Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Greenblatt

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Oncotarget|May 31, 2012
FLT3 in lineage specification and plasticitySarah Greenblatt, Donald Small
Blood|September 13, 2011
Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin miceLi Li, Emily Bailey, Sarah Greenblatt, et al.
Advances in Experimental Medicine and Biology|March 17, 2017
Covalent Modifications of RUNX Proteins: Structure Affects FunctionEzra Blumenthal, Sarah Greenblatt, Guang Huang, et al.
Blood|January 11, 2014
TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivoHayley Ma, Bao Nguyen, Li Li, et al.
Blood|February 11, 2012
Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse modelSarah Greenblatt, Li Li, Christopher Slape, et al.
The Journal of Clinical Investigation|August 11, 2015
Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesisFan Liu, Guoyan Cheng, Pierre-Jacques Hamard, et al.
Cell Reports|September 6, 2018
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying EnzymesPierre-Jacques Hamard, Gabriel E Santiago, Fan Liu, et al.
Experimental Hematology|November 5, 2013
NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human diseaseRachel Rau, Daniel Magoon, Sarah Greenblatt, et al.
Nature Communications|October 31, 2019
TAF1 plays a critical role in AML1-ETO driven leukemogenesisYe Xu, Na Man, Daniel Karl, et al.
Nature Communications|June 9, 2017
Loss of Asxl2 leads to myeloid malignancies in miceJianping Li, Fuhong He, Peng Zhang, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Oncotarget|May 31, 2012
FLT3 in lineage specification and plasticitySarah Greenblatt, Donald Small
Blood|September 13, 2011
Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin miceLi Li, Emily Bailey, Sarah Greenblatt, et al.
Advances in Experimental Medicine and Biology|March 17, 2017
Covalent Modifications of RUNX Proteins: Structure Affects FunctionEzra Blumenthal, Sarah Greenblatt, Guang Huang, et al.
Blood|January 11, 2014
TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivoHayley Ma, Bao Nguyen, Li Li, et al.
Blood|February 11, 2012
Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse modelSarah Greenblatt, Li Li, Christopher Slape, et al.
The Journal of Clinical Investigation|August 11, 2015
Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesisFan Liu, Guoyan Cheng, Pierre-Jacques Hamard, et al.
Cell Reports|September 6, 2018
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying EnzymesPierre-Jacques Hamard, Gabriel E Santiago, Fan Liu, et al.
Experimental Hematology|November 5, 2013
NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human diseaseRachel Rau, Daniel Magoon, Sarah Greenblatt, et al.
Nature Communications|October 31, 2019
TAF1 plays a critical role in AML1-ETO driven leukemogenesisYe Xu, Na Man, Daniel Karl, et al.
Nature Communications|June 9, 2017
Loss of Asxl2 leads to myeloid malignancies in miceJianping Li, Fuhong He, Peng Zhang, et al.
Pageof 2